Global Needle Free Diabetes Management Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Needle Free Diabetes Management Market Insights, Forecast to 2034
Market Analysis and InsightsGlobal Needle Free Diabetes Management Market
Global Needle Free Diabetes Management market is expected to reach to US$ million in 2023, with a positive growth of %, compared with US$ million in 2022. Backed with the increasing demand from downstream industries, Needle Free Diabetes Management industry is evaluated to reach US$ million in 2033. The CAGR will be % during 2023 to 2033.
According to the Global Use of Medicines 2023 released by IQVIA Institute, the global drug expenditure in 2022 was about US$1.48 trillion (excluding COVID vaccine and treatment-related expenses), and it is predicted to grow at a rate of 3%-6% in the next few years. In terms of drug expenditure, this number in China was about 166 billion dollars in 2022. It is expected that the expenditure on medicines will increase in the next few years. From the perspective of demand, the trend of population aging, the increase of residents’ wealth and the improvement of health awareness will drive the demand for medicines.
Global Use of Medicines 2023 shows that the U.S. market spent about US$ 62.9 billion on medicines in 2022 on a net ex-factory basis. Overall growth slows as the Inflation Reduction Act (IRA) spends US$64 billion to reduce prescription drug prices, and the adoption of new treatments is expected to increase over the next few years. Besides, ex-factory discounts and rebates in drug distribution, the impact of patent expiration, and generic or biosimilar competition will also affect the U.S. pharmaceutical market.
Report Covers
This report presents an overview of global Needle Free Diabetes Management market from 2018 to 2033, aiming to help readers to get a comprehensive understanding of global Needle Free Diabetes Management market with multiple angles. Items like regional revenue from 2018 to 2033 and companies’ revenue and gross margin from 2018 to 2023 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2033 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
Zogenix
3M
Antares Pharma Inc.
Glide Pharmaceutical Technologies
Injex Pharma AG
Pharmajet, Inc.
Bioject Medical Technologies
Medtronic
Johnson & Johnson
Pancreum LLC
Tandem Diabetes Care
JDRF
Akra Dermojet
Segment by Type
Insulin Jet Injector
Insulin Pen
Insulin Inhaler
Insulin Patch & Pump
Hospitals
Clinics
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2033
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2033 globally
Chapter 5Product revenue analysis by application from 2018 to 2033 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2033 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2033
Chapter 7Product revenue analysis by type and application from 2018 to 2033 in Europe. Product revenue analysis of each country in Europe from 2018 to 2033
Chapter 8Product revenue analysis by type and application from 2018 to 2033 in China. Product revenue analysis of China from 2018 to 2033
Chapter 9Product revenue analysis by type and application from 2018 to 2033 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2033
Chapter 10Product revenue analysis by type and application from 2018 to 2033 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2033.
Chapter 11Companies’ outline, covering company’s basic information, major business, Needle Free Diabetes Management introduction, etc. Needle Free Diabetes Management Revenue and Gross Margin of each company from 2018 to 2023
Chapter 12MRAResearch’s Conclusions of Needle Free Diabetes Management
Chapter 13Methodology and Data Sources adopted by MRAResearch
Global Needle Free Diabetes Management market is expected to reach to US$ million in 2023, with a positive growth of %, compared with US$ million in 2022. Backed with the increasing demand from downstream industries, Needle Free Diabetes Management industry is evaluated to reach US$ million in 2033. The CAGR will be % during 2023 to 2033.
According to the Global Use of Medicines 2023 released by IQVIA Institute, the global drug expenditure in 2022 was about US$1.48 trillion (excluding COVID vaccine and treatment-related expenses), and it is predicted to grow at a rate of 3%-6% in the next few years. In terms of drug expenditure, this number in China was about 166 billion dollars in 2022. It is expected that the expenditure on medicines will increase in the next few years. From the perspective of demand, the trend of population aging, the increase of residents’ wealth and the improvement of health awareness will drive the demand for medicines.
Global Use of Medicines 2023 shows that the U.S. market spent about US$ 62.9 billion on medicines in 2022 on a net ex-factory basis. Overall growth slows as the Inflation Reduction Act (IRA) spends US$64 billion to reduce prescription drug prices, and the adoption of new treatments is expected to increase over the next few years. Besides, ex-factory discounts and rebates in drug distribution, the impact of patent expiration, and generic or biosimilar competition will also affect the U.S. pharmaceutical market.
Report Covers
This report presents an overview of global Needle Free Diabetes Management market from 2018 to 2033, aiming to help readers to get a comprehensive understanding of global Needle Free Diabetes Management market with multiple angles. Items like regional revenue from 2018 to 2033 and companies’ revenue and gross margin from 2018 to 2023 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2033 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
By Company
Zogenix
3M
Antares Pharma Inc.
Glide Pharmaceutical Technologies
Injex Pharma AG
Pharmajet, Inc.
Bioject Medical Technologies
Medtronic
Johnson & Johnson
Pancreum LLC
Tandem Diabetes Care
JDRF
Akra Dermojet
Segment by Type
Insulin Jet Injector
Insulin Pen
Insulin Inhaler
Insulin Patch & Pump
Segment by Application
Hospitals
Clinics
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2033
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2033 globally
Chapter 5Product revenue analysis by application from 2018 to 2033 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2033 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2033
Chapter 7Product revenue analysis by type and application from 2018 to 2033 in Europe. Product revenue analysis of each country in Europe from 2018 to 2033
Chapter 8Product revenue analysis by type and application from 2018 to 2033 in China. Product revenue analysis of China from 2018 to 2033
Chapter 9Product revenue analysis by type and application from 2018 to 2033 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2033
Chapter 10Product revenue analysis by type and application from 2018 to 2033 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2033.
Chapter 11Companies’ outline, covering company’s basic information, major business, Needle Free Diabetes Management introduction, etc. Needle Free Diabetes Management Revenue and Gross Margin of each company from 2018 to 2023
Chapter 12MRAResearch’s Conclusions of Needle Free Diabetes Management
Chapter 13Methodology and Data Sources adopted by MRAResearch
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices